Table 3 Systemic therapy for pregnancy associated breast cancer
From: Contemporary multidisciplinary treatment of pregnancy-associated breast cancer
Systemic therapy (N = 68 patients delivered live born infants, 36 received chemotherapy therapy) | Number | Percent |
|---|---|---|
Chemotherapy during pregnancy (N = 68) | ||
Yes | 36 | 52.9 |
No | 32 | 47.1 |
Gestational age at initiation of treatment (N = 36) | ||
0-12 weeks (1st trimester) | 0 | 0.0 |
13-27 weeks (2nd trimester) | 29 | 80.6 |
28-40 weeks (3rd trimester) | 7 | 19.4 |
Chemotherapy regimen (N = 36) | ||
Every-3-week AC | 29 | 80.6 |
4 cycles | 21 | 72.4 |
3 cycles | 2 | 6.9 |
2 cycles | 5 | 17.2 |
1 cycle | 1 | 3.4 |
Dose-dense AC | 7 | 19.4 |
4 cycles | 5 | 71.4 |
2 cycles | 2 | 28.6 |
AC × 4 + weekly paclitaxel (12 weeks) | 3 | 8.3 |
Dose-dense AC | 2 | 66.6 |
Every-3-week AC | 1 | 33.4 |
Neoadjuvant chemotherapy (N = 36) | ||
Yes | 8 | 22.2 |
Growth factor support (N = 36) | ||
Yes | 6 | 16.7 |
Pegfilgrastim | 4 | 66.7 |
Filgrastim | 2 | 33.3 |